Introduction
Skeletal muscle is the primary site of postprandial glucose disposal (1) , where the glucose transporter GLUT4 is activated in response to insulin by translocation from internal vesicles to the plasma membrane (2, 3) . In diabetic and pre-diabetic insulin-resistant tissues, insulin driven GLUT4 translocation is compromised (4) . Therapeutic strategies against insulin resistance, including exercise and diet-related interventions, aim at lower postprandial glycemia at least partly by restoring skeletal muscle glucose uptake and enhancing metabolism (5, 6) . One of the most commonly studied classes of gut microbial metabolites are short chain fatty acids (SCFA), which affect host metabolism by acting on mitochondria in skeletal muscle cells, and indeed an important SCFA, butyrate, is correlated with fitness levels (7) . Further, the gut microbiome has a profound influence on inflammatory states (8) and on metabolism during exercise (9) ; as such trained athletes have a distinctly different microbiome compared to sedentary individuals (10) . Endurance exercise requires enhanced energy-generating processes, with increased mitochondrial biogenesis leading to elevated ROS. The gut microbiota regulate mitochondrial biogenesis through modulation of PGC-1α, SIRT1 and AMPK as suggested, for example, by studies where germ-free mice had elevated AMPK and PGC-1α expression in skeletal muscle (11) . The gut microbiota-produced metabolites such as SCFA and secondary bile acids can also contribute to host energy production. In return, mitochondria regulate some aspects of the gut microbiota by modulating intestinal barrier function and mucosal immune responses (12) .
One of the ways in which the microbiome communicates with the body is through production of distinctive biologically active metabolites. Some of these, such as butyrate, have been well studied (13) , and multiple actions have been observed in muscle and other tissue (7, 14) .
Butyrate is mainly derived from "prebiotic" dietary fiber which is undigested in the small intestine, enters the colon and acts as a fermentation substrate for the microbiota (15, 16) .
Dietary phenolics are another class of common prebiotic-type molecules, and this group includes precursor molecules found in unbound form as well as those covalently attached to some dietary fibers such as cereal brans (17) . After microbial action, many potentially bioactive compounds are released and absorbed in the colon from multiple substrates, including phenolics (18, 19) , but the action of these compounds on the body is only beginning to be explored (20, 21) . The situation is complicated by the range of possible -5 - modifications that can occur in vivo such as glucuronidation, sulfation, glutathionylation and methylation (22, 23) ; however, these modified compounds can be present in the blood at high concentrations and remain for long periods of time, increasing the exposure time to body tissues and organs (19) .
Since rodent muscle cells show substantial differences to human cells, including (a) the myogenic programming that regulates differentiation (24) and (b) glucose transport kinetics in response to insulin and GLUT4 expression (25), in the work presented here we specifically chose to use differentiated human muscle cells to understand the mechanisms linking the gut microbiome to glucose uptake. In addition, as immortalized human muscle cell lines rarely retain their muscle phenotype, as part of this work we further characterized and exploited the LHCN-M2 immortalized human skeletal muscle cell line (26) . We then exposed these cells to metabolites of microbial catabolism of commonly-consumed phenolics and examined their effect on glucose uptake and metabolism, especially relevant to post-prandial physiology, insulin responses and type 2 diabetes. - 
-

Materials and Methods
Chemical compounds and reagents
All reagents were purchased from Sigma-Aldrich (Gillingham, UK) unless otherwise stated.
High purity (18.2 MΩ cm -1 ) water supplied by a MilliQ system (Merck Millipore UK, Watford, UK) was used throughout. Ferulic acid 4-O-sulfate (FA4S) and dihydroferulic acid 4-O-sulfate (DHFA-4S) were synthesized according to (27) . Dihydroferulic acid (DHFA) was purchased from Alfa Aesar (Thermo Fisher Scientific, Warrington, UK). Quercetin 3′-Osulfate (Q3S) was synthesized as previously described (28) . Quercetin 
Cell culture and differentiation of LHCN-M2 myoblasts
LHCN-M2 myoblasts are derived from a selected myogenic clone of an immortalized population of human satellite cells, originally from the pectoralis major muscle of a 41-year old Caucasian heart-transplant donor (26) . Myoblasts were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Life Technologies, Thermo Fisher Scientific, UK) supplemented with 5.5 mM glucose, 10% v/v heat-inactivated fetal bovine serum, 10% v/v heat-inactivated newborn calf serum (Gibco), animal-free recombinant human epidermal growth factor (5 µg; PeproTech, London, UK), animal-origin free recombinant human basic fibroblast growth factor (0.5 µg; Gibco) and dexamethasone (200 µg), and sterile-filtered.
Cells were passaged before reaching confluence, at least every 4 d. For experiments, once myoblasts reached ~80-90% confluence they were differentiated to myotubes for 96 h following replacement of growth medium with differentiation medium (DMEM supplemented with 5.5 or 25 mM glucose, 10 or 50 nM recombinant human insulin (Sigma--7 -Aldrich) and 2% horse serum (Gibco)). Differentiation medium was changed every day. The progress of differentiation was monitored daily by observing the formation of elongated and multinucleated myotubes using an inverted microscope (Leica MD IL LED) and characterization of myotube formation is shown in the Results section ( Fig. 1 ). Cells were kept in a humidified atmosphere of 5% CO 2 /95% air at 37 o C and used for experiments over six passages. Sub-culturing was done in 75 or 175 cm 2 flasks and for experiments, cells were seeded on 6-well plates (Corning, Appleton Woods, UK), 100 or 150 mm dishes (Greiner CELLSTAR, Stonehouse, UK) at a density equivalent to ~1.8 x 10 4 cells cm -2 .
Measurement of LHCN-M2 myoblast viability
Viability of LHCN-M2 myoblasts was assessed using the Trypan Blue exclusion assay (31) .
Cells were lifted with 0.05% trypsin-EDTA, resuspended in growth medium, an aliquot was mixed 1:1 (v/v) with 0.4% Trypan Blue-PBS and the cells were counted on the hemocytometer.
Treatment of LHCN-M2 myotubes for protein analysis
Stocks of compounds ( 
Protein analysis by automated Western blotting in nanocapillaries (ProteinSimple)
Whole cell lysates were analyzed for protein by automated western blotting, "WES" (ProteinSimple, Bio-Techne) according to the manufacturer's guidelines. Samples were denatured at 37 o C for 20 min in Bicine/CHAPS. Troponin T (mouse anti-troponin T (cardiac), CT3, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA, USA) was used as a marker of differentiated muscle (33) , PI3K subunit p85α as a marker of the insulin signaling pathway proteins (34) (mouse anti-PI3K (subunit p85α), MAB2998, Novus, Bio-Techne), and rabbit anti-Akt (#9272, Cell Signaling Technology, Beverley, MA, USA) and rabbit anti-phospho-Akt (Ser 473 ) (Cell Signaling Technology) were used to determine the p-Akt/Akt ratio, a marker of insulin signaling pathway activation (35) . Mouse anti-GLUT4 (1F8) was also from Cell Signaling Technology and rabbit anti-GLUT1 (ab115730) was from Abcam (Cambridge, UK). Antibodies were duplexed with mouse antiα-actinin 1 (MAB8279, Novus, Bio-Techne) or rabbit anti--α-actinin ((D6F6) XP #6487, Cell Signaling Technology) as loading controls. Mouse or rabbit secondary antibodies were used neat as supplied (ProteinSimple). Samples were loaded onto the "WES" system at a final total protein concentration of 0.4 mg/ml for troponin T/α-actinin 1 and for PI3K p85α/αactinin 1, 0.5 mg/ml for GLUT4/α-actinin 1 and 0.1 mg/ml for GLUT1/α-actinin and for (p-)Akt/α-actinin. See supplementary figures (S1-S5) for full setup and validation of antibodies. 
Uptake of 2-[1-14 C(U)]-deoxy-D-glucose and D-[ 14 C(U)]-glucose
2´,7´-dichlorofluorescin diacetate (DCFH-DA) assay
The DCFH-DA assay was conducted as described previously (38) . Briefly, cells were washed with PBS, incubated with 10 µM DCFH-DA in PBS at 37 o C for 20 min in darkness, washed again and fluorescence measured on a PheraSTAR FS (BMG LabTech) plate reader (Ex/Em = 485/530 nm). Cells were then scraped and lysed into CellLytic supplemented with 1% (v/v) protease inhibitor cocktail and total protein was measured using the Bradford assay.
Fluorescence was corrected for protein.
Statistical analyses
Data are expressed as mean ± standard error of the mean. The significance of differences between groups of treatments was analyzed by one-way ANOVA and post hoc Tukey's (for unequal sample sizes), Dunnett's (comparing multiple treatments to a single control) or twotailed t-tests accordingly, with variance checks using Levene's test, and with Bonferroni correction where multiple treatments were compared, using SPSS 24. A p value < 0.05 was considered as statistically significant. - 
-
Results
Characterization of differentiated human skeletal muscle LHCN-M2 myotubes
LHCN-M2 myoblasts gradually differentiated into myotubes, as identified by multinucleated fibers formed by fused cells (Fig. 1A) . During the differentiation process α-actinin 1 levels were stable while troponin T increased by ~ 50% every 24 h ( Fig. 1B) . Insulin dosedependently increased 2-[1-14 C(U)]-deoxy-D-glucose ( Fig. 1C ) and D-[ 14 C(U)]-glucose uptake (Fig. 1D ). In contrast, in undifferentiated myoblasts, insulin did not stimulate 2-[1-14 C(U)]-deoxy-D-glucose uptake (Fig. 1E ). Differentiation in high glucose, compared to normal glucose, increased DCF fluorescence as a marker of reactive oxygen species (ROS), which was further amplified by insulin ( Fig. 1F ). Troponin T and GLUT4 protein levels increased with differentiation but were unaffected by glucose and insulin concentration used ( Fig. 1G and H) . In comparison, GLUT1 protein expression was decreased by approximately 25% by the end of the differentiation period in the cells in 5.5 mM glucose and 10 nM insulin, and by a further 10% in the cells in higher glucose and insulin ( Fig. 1I) . Subsequent experiments were performed on cells differentiated for 96 h in either 5.5 mM glucose with 10 nM insulin, or in 25 mM glucose with 50 nM insulin, referred to hereafter as "normal" or "high" glucose/insulin (Glc/Ins) respectively. In the absence of insulin, 5.5 and 25 mM glucose are referred to as "normal" and "high" glucose respectively.
Effect of metabolite mixtures on 2-[1-14 C(U)]-deoxy-D-glucose uptake in differentiated human skeletal muscle LHCN-M2 myotubes
Insulin stimulated the uptake of 2- Notably, the effect of insulin was enhanced in the presence of the phenolic conjugates ( Fig   3D) . Based on these data, the phenolic conjugates exerted a robust insulin-like effect on (deoxy)glucose transport into LHCN-M2 myotubes differentiated both in the presence of normal and high glucose/insulin.
Effect of metabolite mixtures on D-[ 14 C(U)]-glucose uptake in differentiated human skeletal muscle LHCN-M2 myotubes
The assays using D- 
Effect of individual metabolites on 2-[1-14 C(U)]-deoxy-D-glucose and D-[ 14 C(U)]-glucose uptake in differentiated human skeletal muscle LHCN-M2 myotubes
As the most notable effects of the metabolite mixtures were observed under high glucose, and consequently highest metabolic and oxidative stress, we tested individual metabolites predominantly under these conditions. Across all compounds, increases in 2-[1-14 C(U)]deoxy-D-glucose uptake were primarily due to sulfated conjugates: FA4S and DHFA-4S increased uptake by ~15% (p < 0.05) (Fig. 4A ), R3S by ~25% (p < 0.001) ( Fig. 4C ) and IVAS by ~40% in addition to the insulin-stimulated increase (p < 0.001) (Fig. 4D ). The only glucuronide conjugate to exert an effect was R4G, with a ~25% increase (p < 0.01) (Fig. 4C ).
Individual flavonol conjugates were inactive (Fig. 4B ). For uptake of D-[ 14 C(U)]-glucose into LCCN-M2 myotubes, DHFA-4S and R4G decreased intracellular 14 C-label, both independently of insulin ( Fig. 4E, 4G ). Q3G and K3G also lowered intracellular 14 C-label in some conditions (Fig. 4F ). Since IVAS was the most active of the phenolic conjugates on 2- 
Mechanism of action of IVAS on LHCN-M2 myotubes
IVAS dose-dependently increased 2-[1-14 C(U)]-deoxy-D-glucose uptake (Fig. 5A, 5B ), comparable to the action of insulin (Fig. 1C, 1D) . Quantitatively, 2-[1-14 C(U)]-deoxy-Dglucose uptake was higher in myotubes differentiated in normal Glc/Ins, but the high Glc/Ins conditions made the cells more responsive to IVAS when considered as a fold change (Fig.   5B ). IVAS-stimulated uptake of 2-[1-14 C(U)]-deoxy-D-glucose was observed both in the presence and absence of acute insulin, and also in myotubes differentiated under normal or high Glc/Ins (Fig. 5C ). At a high concentration of IVAS (> 10 µM), where its effect reached a plateau, isovanillic acid (IVA) was equally effective (Fig. 5C ) and thus the effects on LHCN-M2 not dependent on the sulfate group of the metabolite.
The PI3K inhibitor wortmannin, and the GLUT4 inhibitor indinavir, both prevented insulinstimulated 2-[1-14 C(U)]-deoxy-D-glucose uptake, but neither had an effect on basal uptake, -13 -as expected. The effect of IVAS was also abolished by the same inhibitors (Fig. 5D ). When treated with IVAS for only 30 min, i.e. bypassing the 4 h pre-treatment, 2-[1-14 C(U)]-deoxy-D-glucose uptake was still increased in LHCN-M2, although less pronounced than with the longer-term treatment, and the inhibitors also prevented the effect of this shorter term incubation (Fig. 5E ).
Expression of Troponin T protein, a differentiation marker, was unaffected by treatment with IVAS in both normal and high Glc/Ins (Fig. 6A ) while GLUT4 expression was substantially increased in both normal and high Glc/Ins by ~60% (p < 0.001) (Fig. 6B ). IVAS treatment restored protein levels of GLUT1, suppressed by 20% under high Glc/Ins conditions, but did not further increase GLUT1 protein expression ( Fig. 6C ). PI3K p85α protein was increased by IVAS in both normal and high Glc/Ins conditions, with a more pronounced effect in the latter (Fig. 6D ). Akt phosphorylation was increased by insulin and inhibited by wortmannin as expected, and was increased by IVAS in both normal and high Glc/Ins conditions (Fig.   6E ). The combination of IVAS and insulin appears to be synergistic for increasing Akt phosphorylation (Fig. 6E ). - 
-
Figure 1: LHCN-M2 myoblasts differentiate to insulin-responsive myotubes.
Myoblasts were grown to confluence, and then in 5.5 mM glucose and 2% serum only for 96 h. Images were taken daily using an inverted microscope at 10X magnification (A). Troponin Numbered green arrows show sites of action of IVAS: 1) PI3K (p85α) is upregulated; 2) Akt phosphorylation is acutely increased; 3) total GLUT4 is upregulated; 4) GLUT4-mediated glucose uptake is increased. Plasma membrane proteins: blue -GLUT4 (also shown stored in cytosolic vesicle); light green -insulin receptor. Ins -insulin; P -phosphate; hexagons represent glucose.
-25 -
Discussion
Human immortalized LHCN-M2 myoblast differentiation to myotubes was accompanied by increased troponin T expression (33) while α-actinin protein, which increases with Z-line formation but not before, was unchanged (40), both as expected. The myotubes were responsive to insulin, a characteristic of skeletal muscle (41). GLUT4 increased with differentiation while GLUT1 decreased, consistent with previous data (42) . Differentiation in high glucose and high insulin increased DCF-fluorescence, a marker of intracellular ROS levels in the LHCN-M2 myotubes, although the overall rate of differentiation was unchanged.
The two conditions, a normal or high glucose and insulin environment, were chosen for many of the experiments here, to compare effects amplified in a higher oxidative stress environment.
The gut microbiome produces a large number of small molecules from its supply of nutrients and other components which reach it via the small intestine. One characteristic is that there are multiple catabolites from a single food source or even from a pure compound (43, 44) .
After consumption of coffee, for example, the gut microbiome metabolites predominantly include DHFA, DHFA-sulfate and FA-sulfate (44) , and these are derived from chlorogenic acids. Whole grains, including cereal brans, give comparable profiles derived from covalently bound phenolic acids (45, 46) . We therefore tested mixtures of some of these metabolites, including conjugates, characteristically derived from either the small intestine or from the colonic microbiota (Fig. 2) . Using a non-metabolizable derivative of glucose, 2-DG, we found that some combinations of metabolites such as ferulic acid derivatives showed an insulin-like effect in cells differentiated in high glucose and high insulin conditions, but not in normal glucose/insulin; while others, such as the resveratrol conjugates and the phenolic acid sulfates mixture, produced a robust effect under both normal and high Glc/Ins. Using labelled glucose as a marker allows the metabolism of glucose to be assessed, leading to end products such as CO 2 or lactate, which are expelled into the medium, or glycogen, which is stored intracellularly. Some of the metabolite mixtures lowered the amount of 14 C-label intracellularly, which, together with the enhanced uptake of glucose evident from the 2-DG data, indicates a stimulation of glucose metabolism leading to enhanced secretion of the 14 Clabel (47) . - 
-
For the ferulic acid mixture, only the sulfated conjugates, FA4S and DHFA-4S, were responsible for the stimulation of glucose transport and the latter alone for the increased metabolism. DHFA-4S, the most active component, is derived almost entirely following the action of the gut microbiota on a range of substrates to produce DHFA, which, after absorption in the colon, is then sulfated by sulfotransferases in the liver. Unconjugated ferulic acid has been shown to increase (deoxy)glucose uptake in primary porcine and human myotubes (48, 49) as well as into muscle L6 myotubes while upregulating GLUT4 and PI3K (50) . However, unconjugated ferulic acid is not a microbial metabolite and does not exist in plasma in the free form in significant concentrations (44) . These data show that the production of DHFA-4S from the gut microbiome could affect glucose uptake and metabolism in muscle, but that the effect would be mostly evident at chronic high glucose concentrations, which exist in metabolic syndrome with impaired glucose tolerance or in diabetes.
The mixture of flavonol conjugates, or individual compounds, exerted only minimal effects on muscle cell uptake of glucose or 2-DG. These conjugates are products of small intestine and hepatic metabolism, and are not derived from the gut microbiota (18, 20) . At very high concentrations, flavonol aglycones were claimed to increase 2-DG uptake in L6 myotubes (51) and quercetin increased glucose uptake via AMPK activation independently of insulin in C2C12 and L6 muscle cells (52, 53), but these aglycones are not present at sufficient concentration in plasma to exert a significant effect (54) .
Resveratrol is a highly bioactive molecule that is absorbed in the small intestine and its presence in blood does not depend on action of the gut microbiota (18) . The resveratrol conjugates increased basal 2-DG uptake and glucose metabolism in both normal and high Glc/Ins myotubes, restoring the lowered 2-DG transport and negating the longer term effect of insulin in the latter. The increased transport was attributable to R4G and R3S, but only R4G was shown to increase metabolism. Resveratrol aglycone has been shown previously to increase (deoxy)glucose uptake in muscle, possibly involving AMPK. Elevated uptake by resveratrol in rodent myotubes was dependent on GLUT4 translocation through activation by sirtuins and AMPK and involving PI3K/Akt pathway activation (55, 56) . -27 - The phenolic sulfates are almost entirely derived from the action of the gut microbiota (29), with subsequent hepatic sulfation. They increased basal 2-DG uptake in normal and high Glc/Ins myotubes and even potentiated the effect of insulin in the latter. Of the compounds tested here, this group displayed the most prominent activity, however, the mixture did not have an effect of glucose metabolism. The increased transport was solely due to IVAS, which also increased basal metabolism in normal and high Glc/Ins when tested as a single metabolite. There are very few reports on the biological activity of IVAS. It has been identified as a plasma metabolite following consumption of berries or cyanidin 3-O-glucoside (29, 57) and as a phase II conjugate of protocatechuic acid (PCA) (58) , but in those studies was (analytically) undistinguishable from VAS. PCA dose-dependently increased (deoxy)glucose uptake in primary human muscle cells (49) , and mimics insulin by activating the insulin receptor to increase glucose uptake in human adipocytes (59) . PCA and its metabolite(s) may have an effect on both pathways that stimulate GLUT4 translocation on L6 myotubes (60) .
In our study, IVAS-stimulated 2-DG uptake was dose-dependent and, as for insulin, exhibited a greater effect in the high Glc/Ins myotubes. Inhibition of IVAS-stimulated uptake by wortmannin and indinavir indicated that the mechanism was dependent on PI3K signaling and GLUT4 translocation (Fig. 7) . IVAS also upregulated GLUT4 and PI3K p85α, as well as activating Akt in the short term. IVAS is relatively hydrophilic with a LogP of -0.73, and so would not enter the myotubes without facilitated transport, while IVA is more hydrophobic (LogP of 1.81) and could enter cells by passive diffusion (61). We therefore suggest that the most likely action of IVAS and IVA is on the insulin receptor on the surface of the LHCN-M2 cell, since these cells do not express the OATs (see supplementary table S1) which are necessary for uptake of molecules such as IVAS (62) .
The data presented here has shown that conjugated catabolites, derived from the action of gut microbiota, affect glucose uptake and metabolism in human skeletal LHCN-M2 myotubes.
Compounds such as DHFA-4S and IVAS were particularly potent, and formation of these compounds absolutely require action of the gut microbiota; DHFA and derivatives are almost absent in ileostomist subjects who have had their colon surgically removed (63) . Studies on foods from which IVAS is known to be ultimately formed by the gut microbiota have shown some beneficial effects in vivo. Supplementation with blueberry bioactive compounds for 6 -28 - weeks improved insulin sensitivity in obese, insulin-resistant participants (64) and, when bread was consumed with berries, less insulin was needed to control the post-prandial glucose (65) .
Interactions between colonic microbiota and host tissues mediated by metabolites such as SCFA have been studied previously, in particular for butyrate (13) , which has the ability to act on many tissues including muscle (7, 14) . The work presented here identifies novel effects of alternative gut microbiome-derived molecules on muscle cells which could have implications on the interaction with skeletal muscle tissue in vivo. Although some activity was observed on phenolic metabolites produced during absorption by the small intestine, the most active molecules were derived from metabolism involving the gut microbiota.
Importantly, these molecules have been detected in blood in humans, and their pathways of post-prandial metabolism have been well described (29, 44) . We have focused here on the effects on glucose uptake and metabolism, as accurate and timely regulation of these processes is vital for correct functioning of muscle cells. With the skeletal muscle accounting for up to 75% of postprandial glucose disposal (4), improving insulin-stimulated glucose uptake in muscle cells through nutritional regulation of the gut microbiome could lead to improved systemic glucose metabolism and enhanced muscle performance with concurrent beneficial effects for the host. Differentiated LHCN-M2 whole cell lysates were analyzed with PI3K p85α and troponin T antibodies at different concentrations run in the same capillary on the automated western blotting system "WES" (ProteinSimple) to test for linearity of signals. Electropherogram view (A) and gel-blot (lane) view (B). The peak areas were used to establish a standard curve for each antibody when duplexed (C). Note, troponin T was chosen as a loading control for PI3K p85α because the MW of the latter is too close to that of α-actinin (1). - 
Figure S5: Antibody validation for Western analysis of Akt and p-Akt with α-actinin.
Differentiated LHCN-M2 whole cell lysates were analyzed for total and phospho-Akt (P-Akt). Antibodies for Akt or P-Akt were run in the same capillary with α-actinin on the automated western blotting system "WES" (ProteinSimple) to test for linearity of signals.
Electropherogram view (A, B) and gel-blot (lane) view (C). The peak areas were used to establish a standard curve for each antibody when duplexed (C). Note, the α-actinin curve consists of mean data of each of the curves run with Akt and P-Akt (D). - 
-
